Carleton BC - Search Results

1

The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments.

Meijer AJM, Li KH, Brooks B, Clemens E, Ross CJ, Rassekh SR, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM, Carleton BC. Meijer AJM, et al. Among authors: carleton bc. Cancer. 2022 Jan 1;128(1):169-179. doi: 10.1002/cncr.33848. Epub 2021 Sep 7. Cancer. 2022. PMID: 34490624 Free article.

2

Pharmacogenomics and its implications for autoimmune disease.

Ross CJ, Katzov H, Carleton B, Hayden MR. Ross CJ, et al. J Autoimmun. 2007 Mar-May;28(2-3):122-8. doi: 10.1016/j.jaut.2007.02.008. Epub 2007 Apr 5. J Autoimmun. 2007. PMID: 17418528

3

Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children.

Ross CJ, Carleton B, Warn DG, Stenton SB, Rassekh SR, Hayden MR. Ross CJ, et al. Ann N Y Acad Sci. 2007 Sep;1110:177-92. doi: 10.1196/annals.1423.020. Ann N Y Acad Sci. 2007. PMID: 17911433

4

Application of principal component analysis to pharmacogenomic studies in Canada.

Visscher H, Ross CJ, Dubé MP, Brown AM, Phillips MS, Carleton BC, Hayden MR. Visscher H, et al. Among authors: carleton bc. Pharmacogenomics J. 2009 Dec;9(6):362-72. doi: 10.1038/tpj.2009.36. Epub 2009 Aug 4. Pharmacogenomics J. 2009. PMID: 19652663

5

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.

Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR; CPNDS Consortium. Ross CJ, et al. Among authors: carleton bc. Nat Genet. 2009 Dec;41(12):1345-9. doi: 10.1038/ng.478. Epub 2009 Nov 8. Nat Genet. 2009. PMID: 19898482

6

The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.

Ross CJ, Visscher H, Sistonen J, Brunham LR, Pussegoda K, Loo TT, Rieder MJ, Koren G, Carleton BC, Hayden MR; CPNDS Consortium. Ross CJ, et al. Among authors: carleton bc. Thyroid. 2010 Jul;20(7):681-7. doi: 10.1089/thy.2010.1642. Thyroid. 2010. PMID: 20578893 Review.

7

Pharmacogenomics and active surveillance for serious adverse drug reactions in children.

Loo TT, Ross CJ, Sistonen J, Visscher H, Madadi P, Koren G, Hayden MR, Carleton BC. Loo TT, et al. Among authors: carleton bc. Pharmacogenomics. 2010 Sep;11(9):1269-85. doi: 10.2217/pgs.10.111. Pharmacogenomics. 2010. PMID: 20860467 Review.

8

Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.

Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, Carleton BC, Kastelein JJ, Hayden MR. Brunham LR, et al. Among authors: carleton bc. Pharmacogenomics J. 2012 Jun;12(3):233-7. doi: 10.1038/tpj.2010.92. Epub 2011 Jan 18. Pharmacogenomics J. 2012. PMID: 21243006

9

Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics.

Visscher H, Amstutz U, Sistonen J, Ross CJ, Hayden MR, Carleton BC. Visscher H, et al. Among authors: carleton bc. J Cardiovasc Pharmacol. 2011 Sep;58(3):228-39. doi: 10.1097/FJC.0b013e3182163b82. J Cardiovasc Pharmacol. 2011. PMID: 21386709 Review.

10

Pharmacogenomics of serious adverse drug reactions in pediatric oncology.

Ross CJ, Visscher H, Rassekh SR, Castro-Pastrana LI, Shereck E, Carleton B, Hayden MR. Ross CJ, et al. J Popul Ther Clin Pharmacol. 2011;18:e134-51. Epub 2011 Mar 21. J Popul Ther Clin Pharmacol. 2011. PMID: 21467604 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

269 results

Search Page

Filters